Viridian Therapeutics

Viridian Therapeutics

Viridian Therapeutics was formed in 2012 as Miragen Therapeutics, focusing on microRNA therapeutics, before a reverse merger with an antibody company in 2021 and a subsequent rebranding. Scott Myers took over as CEO in 2020, shifting the firm's strategy toward thyroid eye disease, a niche autoimmune indication with no competition for biologics at the time of its pivot. The company runs a focused development strategy with two lead programs: VRDN-001, an intravenous anti-IGF-1R antibody in Phase 3 trials, and VRDN-003, a subcutaneous follow-on candidate designed for self-administration. Both target thyroid eye disease, a condition affecting approximately 100,000 patients in the United States. The firm's treasury is funded entirely through equity raises — at-the-market programs and public offerings — rather than partnership milestones or licensing revenue, with balance-sheet cash financing all R&D directly. Deployment is concentrated in clinical trials, manufacturing scale-up, and regulatory preparation across US and European markets. Viridian employs fewer than 100 professionals, operating from a single headquarters in Waltham, Massachusetts, with clinical operations extending to trial sites across the United States and Europe. As of September 2024, the firm reported roughly $800 million in cash and equivalents on its balance sheet, positioning it to fund operations through its first potential FDA approval without additional dilutive raises (per the firm's SEC filings, September 2024). The firm does not maintain adjacent investment vehicles, venture arms, or philanthropic foundations, operating solely as a therapeutics developer. The firm's structural differentiator is its balance-sheet-funded independence: it advances its entire pipeline without pharma partnerships, retaining full commercial rights to any approved therapies. This capital-intensive approach — sustained by repeated equity raises targeting specialist biotech investors — means its success hinges on clinical data from the THRIVE Phase 3 readout expected in 2026, creating a binary clinical catalyst that defines the firm's next decade.